There is a substantial heterogeneity in adoption of multi-gene assays in Europe.

In a survey among physicians with at least 5 years of experience in treatment of breast cancer, a majority of respondents indicated they would use multi-gene assays in clinical practice, but the main perceived barriers for usage are reimbursement, price and lack of availability, according to the survey results presented by Dr Matti Aapro of the Multidisciplinary Oncology Institute, Geneva, Switzerland.

Read the article in full here.

Source: ESMO